Achieving strong gene editing results is only the first step toward successful non-viral cell therapies. Long-term success depends on developing processes that consistently deliver high-quality cells, support scalability, and translate effectively into manufacturing environments.
In this webinar, we explore the key considerations for building scalable non-viral gene editing workflows for cell therapy applications.
Topics include
- Strategies for gene delivery
- Maintaining critical quality attributes such as cell viability and expansion
- Designing processes with scale-up and manufacturing requirements in mind from the earliest stages of development.
Viewers will gain insight into non-viral gene editing in T cells, NK cells, and CD34+ stem cells using electroporation-based approaches like Lonza’s 4-Nucleofector® LV Unit PRO.
Real-world data demonstrates the delivery of CRISPR knock-out, knock-in, and transposon-based cargos, highlighting how editing performance can be balanced with downstream process needs. In addition, we also cover how process development can be leveraged to optimize electroporation conditions, support closed and scalable workflows, and facilitate progression toward GMP-ready manufacturing.
By connecting early research activities with manufacturing considerations, this session provides a practical framework for advancing non-viral gene-edited cell therapies from development through commercialization.
